Added to YB: 2025-08-21
Pitch date: 2025-08-20
ALEC [bullish]
Alector, Inc.
-31.96%
current return
Author Info
No bio for this author
Company Info
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases.
Market Cap
$135.3M
Pitch Price
$2.19
Price Target
N/A
Dividend
N/A
EV/EBITDA
1.12
P/E
-1.15
EV/Sales
-1.71
Sector
Biotechnology
Category
special_situation
Alector Therapeutics: Is the negative sentiment justified?
ALEC: Latozinemab Phase 3 FTD-GRN readout mid-Q4. Addresses progranulin deficiency like enzyme replacement therapy. Phase 2 showed biomarker improvements vs historical controls. GSK invested $700M upfront. Market prices ~20% success probability (current $220M mcap, -$80M EV) vs estimated 50% POS. Failure of Prevail's gene therapy not comparable. $1B peak sales potential.
Read full article (7 min)